Apellis Pharmaceuticals, Inc.
Apellis is a biotechnology company dedicated to developing life-changing medicines for challenging diseases by controlling the complement cascade, a part of the immune system. They have pioneered a new class of complement medicine with two approved therapies targeting C3, aiming to transform treatment across a broad range of serious diseases. Their mission is driven by courageous science and compassion, with a focus on innovation, patient advocacy, and corporate responsibility.
Industries
Nr. of Employees
large (251-1000)
Apellis Pharmaceuticals, Inc.
Patents
Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
US-11661441-B2
View Details
Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
US-11661441-B2
View DetailsProducts
Empaveli (pegcetacoplan) injection — subcutaneous formulation
Pegcetacoplan formulated for subcutaneous injection; listed with associated U.S. patents.
Syfovre (pegcetacoplan) injection — intravitreal formulation
Pegcetacoplan formulated for intravitreal injection; listed with associated U.S. patents and described as an approved retinal therapy.
Empaveli (pegcetacoplan) injection — subcutaneous formulation
Pegcetacoplan formulated for subcutaneous injection; listed with associated U.S. patents.
Syfovre (pegcetacoplan) injection — intravitreal formulation
Pegcetacoplan formulated for intravitreal injection; listed with associated U.S. patents and described as an approved retinal therapy.
Services
Comprehensive product support for patients and healthcare providers delivered via dedicated websites and phone lines.
Programmatic review and provision of investigational therapy access for individual patients (CU) or groups (EAP) when appropriate and consistent with core principles.
Centralized medical information contact for inquiries and reporting related to therapies.
Comprehensive product support for patients and healthcare providers delivered via dedicated websites and phone lines.
Programmatic review and provision of investigational therapy access for individual patients (CU) or groups (EAP) when appropriate and consistent with core principles.
Centralized medical information contact for inquiries and reporting related to therapies.
Expertise Areas
- Complement therapeutics (C3 targeting)
- Ophthalmology (retinal disease, geographic atrophy)
- Rare disease therapeutics
- Clinical trial management
Key Technologies
- C3-targeted complement inhibitors
- Injectable biologic formulations (subcutaneous and intravitreal)
- Clinical development platforms
- Patient support and call-center platforms
News & Updates
First-ever therapy for geographic atrophy, a leading cause of blindness
Apellis developed the first therapy targeting C3 for geographic atrophy, marking a significant advancement in treatment for this leading cause of blindness.
First-ever therapy for geographic atrophy, a leading cause of blindness
Apellis developed the first therapy targeting C3 for geographic atrophy, marking a significant advancement in treatment for this leading cause of blindness.